Christopher Bredeson

15.6k total citations · 1 hit paper
170 papers, 6.7k citations indexed

About

Christopher Bredeson is a scholar working on Hematology, Oncology and Public Health, Environmental and Occupational Health. According to data from OpenAlex, Christopher Bredeson has authored 170 papers receiving a total of 6.7k indexed citations (citations by other indexed papers that have themselves been cited), including 109 papers in Hematology, 54 papers in Oncology and 42 papers in Public Health, Environmental and Occupational Health. Recurrent topics in Christopher Bredeson's work include Hematopoietic Stem Cell Transplantation (88 papers), Acute Lymphoblastic Leukemia research (38 papers) and Acute Myeloid Leukemia Research (33 papers). Christopher Bredeson is often cited by papers focused on Hematopoietic Stem Cell Transplantation (88 papers), Acute Lymphoblastic Leukemia research (38 papers) and Acute Myeloid Leukemia Research (33 papers). Christopher Bredeson collaborates with scholars based in Canada, United States and United Kingdom. Christopher Bredeson's co-authors include Mary M. Horowitz, Hillard M. Lazarus, John P. Klein, J. Douglas Rizzo, David I. Marks, Bruce M. Camitta, Navneet S. Majhail, Robert Peter Gale, Mary Eapen and Lothar Huebsch and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Christopher Bredeson

163 papers receiving 6.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Long-Term Survival and Late Deaths after Allogeneic Bone Marrow Transplantation

1999 525 citations John R. Wingard, Daniel J. Weisdorf et al. profile →

Peers

Countries citing papers authored by Christopher Bredeson

Since Specialization

Citations

This map shows the geographic impact of Christopher Bredeson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Christopher Bredeson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Christopher Bredeson more than expected).

Fields of papers citing papers by Christopher Bredeson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Christopher Bredeson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Christopher Bredeson. The network helps show where Christopher Bredeson may publish in the future.

Co-authorship network of co-authors of Christopher Bredeson

This figure shows the co-authorship network connecting the top 25 collaborators of Christopher Bredeson. A scholar is included among the top collaborators of Christopher Bredeson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Christopher Bredeson. Christopher Bredeson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Donor Type Does Not Impact Late Graft Failure Following Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis 2025 ·Transplantation and Cellular Therapy ·(unknown), Mei‐Jie Zhang, (unknown), Rizwan Romee, Navneet S. Majhail, Monzr M. Al Malki, Joseph H. Antin, Cara L. Benjamin, Christopher Bredeson, Saurabh Chhabra, Michael R. Grunwald, Yoshihiro Inamoto, Christopher G. Kanakry, Filippo Milano, Robert J. Soiffer, Scott R. Solomon, (unknown), Claudio G. Brunstein, Corey Cutler	0
2	Developing Organizational Requirements to Standardize Delivery and Improve Quality of Acute Leukemia Care in Ontario 2024 ·Current Oncology ·(unknown), (unknown), (unknown), (unknown), Mitchell Sabloff, Rena Buckstein, (unknown), Karen Yee, (unknown), Christopher Bredeson	1
3	Outcomes with low dose anti‐thymocyte globulin based graft versus host disease prophylaxis after mismatched unrelated donor allogeneic hematopoietic cell transplantation 2024 ·European Journal Of Haematology ·(unknown), (unknown), (unknown), Harold Atkins, Christopher Bredeson, (unknown), Natasha Kekre, David Allan, Ram Vasudevan Nampoothiri	1
4	Impact of Donor Age on Allogeneic Hematopoietic Cell Transplantation Outcomes in Older Adults with Acute Myeloid Leukemia 2023 ·Transplantation and Cellular Therapy ·Muhammad Bilal Abid, Noel Estrada‐Merly, Mei‐Jie Zhang, Karen Chen, David Allan, Christopher Bredeson, Mitchell Sabloff, Guru Subramanian Guru Murthy, Talha Badar, Shahrukh K. Hashmi, Mahmoud Aljurf, Mark R. Litzow, Partow Kebriaei, Christopher S. Hourigan, Wael Saber	9
5	Continuous Alloreactive T Cell Depletion and Regulatory T Cell Expansion for the Treatment of Steroid- Refractory or Dependent Chronic GVHD – a Multicentre Phase II Clinical Trial (CARE Trial) 2021 ·Transplantation and Cellular Therapy ·Imran Ahmad, Janet J. Bijl, Sabine Ivison, Eshetu G. Atenafu, Tony Panzarella, Raewyn Broady, David Szwajcer, Irwin Walker, Dennis Dong Hwan Kim, Christopher Bredeson, Ronan Foley, Donna E. Hogge, David Allan, Jean‐Sébastien Delisle, Kirk R. Schultz, Donna A. Wall, Megan K. Levings, Denis‐Claude Roy	1
6	Early Warning of Infection in Patients Undergoing Hematopoietic Stem Cell Transplantation Using Heart Rate Variability and Serum Biomarkers 2021 ·Transplantation and Cellular Therapy ·(unknown), Heidi Oi‐Yee Li, Christophe L. Herry, Nathan Scales, Paul MacPherson, (unknown), Christopher Bredeson, Lothar Huebsch, Michael Hodgins, Andrew Seely	7
7	Autologous Hematopoietic Cell Transplantation for Treatment-Refractory Relapsing Multiple Sclerosis: Position Statement from the American Society for Blood and Marrow Transplantation 2019 ·Biology of Blood and Marrow Transplantation ·Jeffrey A. Cohen, Laura Baldassari, Harold Atkins, James D. Bowen, Christopher Bredeson, Paul A. Carpenter, John R. Corboy, Mark S. Freedman, Linda M. Griffith, Robert Lowsky, Navneet S. Majhail, Paolo A. Muraro, Richard A. Nash, Marcelo C. Pasquini, Stefanie Sarantopoulos, Bipin N. Savani, Jan Storek, Keith M. Sullivan, George E. Georges	72
8	Choosing Wisely BMT: American Society for Blood and Marrow Transplantation and Canadian Blood and Marrow Transplant Group's List of 5 Tests and Treatments to Question in Blood and Marrow Transplantation 2018 ·Biology of Blood and Marrow Transplantation ·Sita Bhella, Navneet S. Majhail, (unknown), Luciano J. Costa, Andrew Daly, Christopher E. Dandoy, Zachariah DeFilipp, (unknown), Alison Gulbis, Lisa K. Hicks, Mark Juckett, Nandita Khera, Amrita Krishnan, George B. Selby, Nirav N. Shah, Melisa Stricherz, Auro Viswabandya, Christopher Bredeson, Matthew D. Seftel	31
9	Payment and Care for Hematopoietic Cell Transplantation Patients: Toward a Specialized Medical Home for Complex Care Patients 2017 ·Biology of Blood and Marrow Transplantation ·James Gajewski, Mark McClellan, Navneet S. Majhail, Parameswaran Hari, Christopher Bredeson, Richard T. Maziarz, Charles F. LeMaistre, Michael Lill, Stephanie Farnia, Krishna V. Komanduri, Michael Boo	4
10	A national survey of screening and management of hypogammaglobulinemia in Canadian transplantation centers 2017 ·Transplant Infectious Disease ·(unknown), Greg Knoll, Jason Tay, Christopher Bredeson, D. William Cameron, Juthaporn Cowan	9
11	Personalizing Busulfan-Based Conditioning: Considerations from the American Society for Blood and Marrow Transplantation Practice Guidelines Committee 2016 ·Biology of Blood and Marrow Transplantation ·Jeanne Palmer, Jeannine S. McCune, Miguel‐Angel Perales, David I. Marks, Joseph Bubalo, Mohamad Mohty, John R. Wingard, Angélo Paci, Moustapha Hassan, Christopher Bredeson, Joseph Pidala, Nina Shah, Paul Shaughnessy, Navneet S. Majhail, Jeff Schriber, Bipin N. Savani, Paul A. Carpenter	110
12	Heterogeneity in Studies of Mesenchymal Stromal Cells to Treat or Prevent Graft-versus-Host Disease: A Scoping Review of the Evidence 2016 ·Biology of Blood and Marrow Transplantation ·(unknown), (unknown), Risa Shorr, Natasha Kekre, Christopher Bredeson, David Allan	66
13	Rationale and design of platelet transfusions in haematopoietic stem cell transplantation: the PATH pilot study 2016 ·BMJ Open ·Jason Tay, David Allan, Sara Beattie, Christopher Bredeson, Dean Fergusson, Dawn Maze, Mitchell Sabloff, Kednapa Thavorn, Alan Tinmouth	6
14	PO-0667: Second malignancies after TBI in AHCT for relapsed follicular lymphoma 2016 ·Radiotherapy and Oncology ·(unknown), Rajeev S. Samant, Mitchell Sabloff, (unknown), Christopher Bredeson, Lothar Huebsch, P. Genest, Paul Cross	5
15	Prospective cohort study comparing intravenous busulfan to total body irradiation in hematopoietic cell transplantation 2013 ·Blood ·Christopher Bredeson, Jennifer Le‐Rademacher, Kazunobu Kato, John F. DiPersio, Edward Agura, Steven M. Devine, Frederick R. Appelbaum, Marcie Tomblyn, Ginna G. Laport, Xiaochun Zhu, Philip L. McCarthy, Vincent T. Ho, Kenneth R. Cooke, (unknown), (unknown), J. Douglas Rizzo, (unknown), Marcelo C. Pasquini	88
16	Significant Improvement in Survival After Allogeneic Hematopoietic Cell Transplantation During a Period of Significantly Increased Use, Older Recipient Age, and Use of Unrelated Donors 2013 ·Journal of Clinical Oncology ·Theresa Hahn, Philip L. McCarthy, Anna Hassebroek, Christopher Bredeson, James Gajewski, Gregory A. Hale, Luis Isola, Hillard M. Lazarus, Stephanie J. Lee, Charles F. LeMaistre, Fausto R. Loberiza, Richard T. Maziarz, J. Douglas Rizzo, Steven Joffe, Susan K. Parsons, Navneet S. Majhail	175
17	Improved Survival with Intravenous Busulfan (IV BU) Compared to Total Body Irradiation (TBI)-Based Myeloablative Conditioning Regimens: A CIBMTR Prospective Study 2013 ·Biology of Blood and Marrow Transplantation ·Christopher Bredeson, Jennifer Le‐Rademacher, Xiaochun Zhu, (unknown), Kazunobu Kato, (unknown), Yiping Sun, (unknown), Vincent T. Ho, Philip L. McCarthy, Kenneth R. Cooke, J. Douglas Rizzo, Marcelo C. Pasquini	3
18	Similar outcomes using myeloablative vs reduced-intensity allogeneic transplant preparative regimens for AML or MDS 2011 ·Bone Marrow Transplantation ·Selina M. Luger, Olle Ringdén, M-J Zhang, Waleska S. Pérez, Michael R. Bishop, Martin Bornhäuser, Christopher Bredeson, Mitchell S. Cairo, Edward A. Copelan, Robert Peter Gale, Sergio Giralt, Zafer Gülbaş, Vikas Gupta, Gregory A. Hale, Hillard M. Lazarus, Victor Lewis, Michael Lill, Phillip McCarthy, Daniel Weisdorf, Michael A. Pulsipher	194
19	Effect of Age on Outcome of Reduced-Intensity Hematopoietic Cell Transplantation for Older Patients With Acute Myeloid Leukemia in First Complete Remission or With Myelodysplastic Syndrome 2010 ·Journal of Clinical Oncology ·Brian McClune, Daniel J. Weisdorf, Tanya L. Pedersen, Gisela Tunes da Silva, Martin S. Tallman, Jorge Sierra, John F. DiPersio, Armand Keating, Robert Peter Gale, Biju George, Vikas Gupta, Theresa Hahn, Luis Isola, Madan Jagasia, Hillard M. Lazarus, David I. Marks, Richard T. Maziarz, Edmund K. Waller, Christopher Bredeson, Sergio Giralt	338
20	Outpatient total body irradiation as a component of a comprehensive outpatient transplant program 2002 ·Bone Marrow Transplantation ·Christopher Bredeson, George Perry, (unknown), Sheryl McDiarmid, Isabelle Bence‐Bruckler, Harry Atkins, (unknown), (unknown), Joseph Mıkhael, P. Genest, Lothar Huebsch	8

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact